TMC launches new biotech partnership with Republic of Korea

international collaboration

The Texas Medical Center and KBIOHealth have launched the TMC Republic of Korea BioBridge. Photo via LinkedIn.

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

From Your Site Articles
Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

Prabhdeep Singh Sekhon, CEO of Gold H2, joins the Houston Innovators Podcast. Photo courtesy of Gold H2

Newly named CEO to lead Houston gold hydrogen biotech co. into high-growth phase

HOUSTON INNOVATORS PODCAST EPISODE 239

Using microbes to sustainably unlock low-cost hydrogen sounds like the work of science fiction, but one Houston company is doing just that.

Gold H2, a spin-off company from Cemvita, has bioengineered subsurface microbes to use in wells to consume carbon and generate clean hydrogen. The technology was piloted two years ago by Cemvita, and now, as its own company with a new CEO, it's safe to say Gold H2's on its way.

"First of all, that was groundbreaking," Prabhdeep Singh Sekhon, CEO of Gold H2, says of the 2022 pilot in the Permian Basin, "to be able to use bugs to produce hydrogen within a couple of days."

"2024 is supposed to be the year where Gold H2 takes off," Sekhon, who joined the company in April, tells the Houston Innovators Podcast. "It was one of those opportunities that I couldn't turn down. I had been following the company. I thought, 'here is this innovative tech that's on the verge of providing a ground-breaking solution to the energy transition — what better time to join the team.'"

Sekhon shares on the show how his previous roles at NextEra Energy Resources and Hess have prepared him for Gold H2. Specifically, as a leader on NextEra’s strategy and business development team, he says he was tasked with figuring out what the energy industry looks like in the next five, 10, and 20 years.

"Green hydrogen was a huge buzz, but one of the things I realized when I started looking at green hydrogen was that it's very expensive," Sekhon says. "I wanted to look at alternatives."

This journey led him to what Cemvita was doing with gold hydrogen, Sekhon says, explaining that the ability to use biotechnology to provide a new revenue stream from the mostly used up wells struck him as something with major potential.

"The idea of repurposing existing oil and gas assets to become hydrogen assets, leveraging current infrastructure to drive down overall deliver costs — to me I thought, 'wow, if they can make this works, that's brilliant,'" he says.

Now, as CEO, Sekhon gets to lead the company toward these goals, which include expanding internationally. He explains on the show that Gold H2 is interested in expanding to any part of the world where there's interest in implementing their biotech. In order to support the growth, Sekhon says they are looking to raise funding this year with plans for an additional round, if needed, in 2025.

"When we compare our tech to the rest of the stack, I think we blow the competition out of the water," Sekhon says, explaining that Gold H2's approach to gold hydrogen development is novel when you look at emerging technology in the space. "We're using a biological process — cheap bugs that eat oil for a living."

With its blend of biotechnology, conservation, and education, RioRaiz seeks to inspire a new generation of conservationists. Photo via RioRaiz/Instagram

Innovative Houston nonprofit taps into biotech to preserve ecological biodiversity

conservation tech

For centuries, humans have been negatively impacting the natural world around them. A Houston organization is looking to leave an impact on the environment — but this time for the better.

Based in Houston, RioRaiz is a 501c3 nonprofit organization charting a unique course in the world of conservation and education. Founded in March of 2021, RioRaiz – meaning "root of the river" in Spanish, a nod to its deep-rooted connection with South American culture – seeks to preserve biodiversity through biotechnology and offer transformative learning experiences to contribute to a healthier planet.

Led by Jeff Carlson, the president and CEO, RioRaiz's mission is driven by three core pillars: conservation, scientific discovery, and education.

Currently, the nonprofit's efforts are focused on regions on the edge of ecological disruption, specifically the East Texas area and the Tropical Andes. In Texas, the organization aims to expand the biome of the Big Thicket National Preserve in Kountze as well as engaging locals by hosting clean-up drives. In the Andes, RioRaiz aspires to establish biological corridors between national parks and natural reserves, diminishing potential disruptions to animal migration patterns.

The timeline for these critical initiatives, Carlson said, hinges on donations.

"We have a list of priorities that is cataloged from input from our scientific collaborators, as well as our ability to deliver on our promises to our donors and supporters,” Carlson said.

Partnerships form a critical role in RioRaiz's work, notably those with academic institutions in the United States and Colombia. One of these collaborations saw Carlson spend three months in Colombia, working with the local Páez tribe, also known as the Nasa, to explore the potential of their traditional medicines for modern treatments.

"We're really excited to learn and to share our techniques and our knowledge," Carlson said, underlining the organization's commitment to partnering with traditional and indigenous knowledge sources.

With its blend of biotechnology, conservation, and education, RioRaiz seeks to inspire a new generation of conservationists. By offering an intimate virtual glimpse into the world's biomes, the nonprofit aims to instill a deep-rooted respect for nature and encourage sustainable action.

"If you expose students to these different kinds of environments at an early age, that might inspire somebody to go into conservation," Carlson said.

With a progressive effort, RioRaiz is harnessing the power of virtual reality to redefine education. The organization uses specialized filming equipment during its expeditions, capturing moments like the discovery of new species or conducting bio surveys. RioRaiz's visually compelling stories will surpass language barriers, transporting students virtually to different biomes. In time, Carlson hopes to distribute pre-loaded systems to communities with limited internet access, taking the classroom to every corner of the world. These virtual reality experiences are expected to launch within the next year.

"We want to bring the rainforest into the classroom," Carlson said.

Through its work, RioRaiz aims to demonstrate that the route to a sustainable future lies not just in face-to-face interactions, but in a global, interconnected approach to education and conservation. Its vision is clear — to grow far beyond traditional reaches, preserving biodiversity and fostering a healthier world.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

8+ can't-miss Houston business and innovation events in January

where to be

Editor's note: Kick off 2026 by hearing insightful talks and making meaningful connections in Houston's innovation scene. From networking workshops to presentations from major industry leaders, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Jan. 13 – Financing the Future

Hear from James Blake, head of capital markets at Fervo Energy, in this informative talk. Blake will cover the current investment landscape for geothermal power, how geothermal projects are structured and the role of policy incentives and innovative financing models in moving the industry forward. A small reception follows.

This event is Tuesday, Jan. 13, from 5:30-7:30 p.m. at the Ion. Register here.

Jan. 13 – Your Path to the Boardroom

Visit Sesh Coworking to hear from Keith Dorsey, an executive advisor and author of The Boardroom Journey, as he shares insights and lessons from hundreds of corporate board members and presents an actionable roadmap for women at every stage of their careers. Dorsey will speak on what "optimal diversity” means in the boardroom, how purpose-driven leaders sustain resilience under relentless pressure and why inclusive leadership is non-negotiable for growth and innovation.

This event is Tuesday, Jan. 13, from 6-8 p.m. at Sesh Coworking. Register here.

Jan. 14 — A Conversation with Dr. Wayne J. Riley on Leading Through Healthcare Transformation

Rice Business Partners will host Dr. Wayne J. Riley, president of SUNY Downstate Health Sciences University, for a moderated discussion with Dean Peter Rodriguez. Riley will share insights on leading complex healthcare organizations in an era of unprecedented industry challenges and reflect on his time at the Jones Graduate School of Business.

This event is Wednesday, Jan. 14, from 6:30-8:30 p.m. at McNair Hall on Rice University's campus. Register here.

Jan. 14 — VDW: Igniting Connections for Startup Success

Entrepreneurial communications instructor Diana Massaro will lead Lilie's latest Venture Development Workshop, focused on soft skills like clear communication, active listening and compelling introductions. Attendees will gain a personalized networking game plan and communication tools to turn casual encounters into meaningful relationships to support their ventures or careers.

This event is Wednesday, Jan. 14, from 6-7:30 p.m. at the Liu Idea Lab for Innovation and Entrepreneurship on Rice University's campus. Register here.

Jan. 21 — Upstream: Digital Tech Meetup

This month's Upstream: Digital Tech Meetup will explore how AI and real-time monitoring are being applied in safety-critical offshore environments, what’s working today, where the biggest gaps remain going into 2026 and how operators and service companies are approaching adoption. Expect to hear from leaders at NOV, Incom Solutions, Timbergrove and others.

This event is Wednesday, Jan. 21, from 8:30-10:30 a.m. at the Ion. Find more information here.

Jan. 22 — HEAD AND HEART: Leading Technology with Humanity While Everything Changes

Hear from Chris Hyams, former CEO of Indeed, at the latest installment of Rice's Master of Engineering Management & Leadership Seminar Series. Hyams will present on the intersection of technology, humanity and change—and how AI is reshaping all three.

This event is Thursday, Jan. 22, at 6 p.m. at Duncan Hall on Rice University's campus. Find more information here.

Jan. 22 – NASA Tech Talk

This month's NASA Tech Talks will feature a special delegation from the UK Science and Technology Network. Expect to hear from a panel of UK space experts, followed by a fireside chat featuring David Alexander, head of the Rice Space Institute, and Meganne Christian, ESA reserve astronaut and senior exploration manager.

This event is Thursday, Jan. 22, from 6-7 p.m. at the Ion. Find more information here.

Jan. 29 – Ignition Hub Startup Career Fair

Lilie will host the Ignition Hub Startup Career Fair this month in partnership with Rice University’s Center for Career Development and Career Development Office. The fair will bring together some of the most innovative, high-growth companies to offer Rice students exciting opportunities. Startups can apply to be considered for the fair. The event is open to Rice University undergraduate, graduate, MBA, and PhD students.

This event is Thursday, Jan. 29, at Grand Hall on Rice University's campus. Find more information here.

Jan. 29 – Health Policy Symposium: Value-Based Care & the Health Care Workforce

The Humana Integrated Health Systems Science Institute at the University of Houston will host its latest Health Policy Symposium this month, focused on the evolving landscape of value-based care and the importance of preparing and strengthening the health care workforce. Hear keynote addresses from leaders at Humana, UH, the American Medical Association and Houston Health Department.

This event is Thursday, Jan. 29, from 11:30 a.m.-1:30 p.m. at the Tilman J. Fertitta Family College of Medicine on Rice University's campus. Find more information here.

Jan. 30 — GHP Annual Meeting

The Greater Houston Partnership's premier event will highlight the region’s progress, honor visionary leadership and set the tone for the year ahead. Hear reflections from outgoing board chair, Gretchen Watkins (former -president of Shell USA); welcome incoming board chair, Armando Perez (EVP of H-E-B Houston); and more

This event is Friday, Jan. 30, from 11:30 a.m.-1:30 p.m. at Hilton Americas. Find more information here.

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totaling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

View All Listings